Skip to content

Effect of propolis use on blood level of il-17 in ulcerative oral lichen planus patients.

Effect of propolis use on blood level of il-17 in ulcerative oral lichen planus patients

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
IRCT
Registry ID
IRCT2013010111976N1
Enrollment
30
Registered
2013-02-10
Start date
2013-02-04
Completion date
Unknown
Last updated
2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

oral lichen planus. lichen planus

Interventions

propolis capsule 500 mg daily for one month.
Treatment - Drugs
propolis capsule 500 mg daily for one month

Sponsors

Deputy of Research of Tabriz University of Medical Sciences
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 70 Years

Inclusion criteria

Inclusion criteria: Inclusion criteria: patients with ulcerative oral lichen planus with clinical manifestations and histopathological criteria including: 1-Areas of hyper parkeratosis or hyper orthokeratosis, often with thickening of granular cell layer and saw-toothd appearance to the retepegs. 2-liquefaction degeneration or necrosis of basal cell layer. 3-sub epithelial band like infiltration of T lymphocyte and macrophage. Exclusion criteria: any factor that cause lichenoid reaction like as drug use or presence of amalgam restoration adjucent to lesions; any disease that suppresses immune system,such as HIV or Iv drug abuse,and any disease in which doing biopsy has medical complications; use of drug during one month ago for treatment of olp or use of antibiotic or corticosteroid or any drug that can suppress lymphocyte activity(for confidence that drugs don't change serum level of il-17); report of dysplasia or malignancy in patients pathology; history of dermal or digestive hypersensitivity to propolis; unwillingness to participate in study at any stages and report of side effects from patients or researchers.

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

MeasureTime frame
Serum level of il-17. Timepoint: At the begining of research-one month later. Method of measurement: Elisa kit (ebio science company).

Secondary

MeasureTime frame
Size of lesions. Timepoint: At the beigining of the research-one month later. Method of measurement: Mesurment of lesion size at the begining of research with digital colis and then mark the changes by researcher in future follwing.;Pain and burning sensation. Timepoint: At the beigining of the research-one month later. Method of measurement: VAS scale.

Countries

Iran (Islamic Republic of)

Contacts

Public ContactDr Reza Tavakoli Ataabadi

Dental Faculty of Tabriz University of Medical Sciences

drtavakolireza.dds@gmail.com+98 41 1335 5965

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026